Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Mary Kaminski, PA
CONTACT
Lead
National Institute of Allergy and Infectious Diseases (NIAID)
With
CTOT-46 will enroll up to up to 26 highly sensitized kidney transplant candidates at 3 centers. There will be a safety run-in and 2 treatment cohorts to assess the safety and pharmacodynamics of CART-BCMA and huCART-19. Following screening and enrollment, the subject will undergo leukapheresis to collect T cells for CAR T cell manufacturing. Subsequently, subjects will undergo lymphodepleting chemotherapy followed by CART-BCMA and huCART19 cell infusions. A secondary objective is to evaluate the efficacy of study treatment to reduce cPRA and determine the duration cPRA reduction.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted